In DLBCL patients, the prevalence of MYD88 mutations was 18.37%, while the prevalence of TP53 mutations was 28.57%), as shown in Table 1, and in the healthy control group, both MYD88 and TP53 were negative for mutations (100% wild type). Here, TP53 is linked to diffuse large B-cell lymphoma.